Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emactuzumab with Paclitaxel and Bevacizumab in Platinum-Resistant Ovarian Cancer
NCT02923739Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2017
- Primary completion
- Sep 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of emactuzumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety of Administration of Paclitaxel, Bevacizumab and Emactuzumab at 4 weeks and Progression-Free Survival at 32 weeks. Started May 2017; status: terminated.
02
Drugs
emactuzumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02923739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923739.